Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai, T Ito… - Thoracic …, 2018 - Wiley Online Library
Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
O Kanai, YH Kim, Y Demura, M Kanai, T Ito… - Thoracic …, 2018 - europepmc.org
Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
[PDF][PDF] Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai, T Ito, K Fujita… - 2018 - core.ac.uk
Background: The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai, T Ito… - Thoracic …, 2018 - search.proquest.com
Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai, T Ito… - Thoracic …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
[HTML][HTML] Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai, T Ito… - Thoracic …, 2018 - ncbi.nlm.nih.gov
Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
金井 - Thoracic cancer, 2018 - cir.nii.ac.jp
Background: The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai… - Thoracic …, 2018 - repository.kulib.kyoto-u.ac.jp
Results: The RR and median PFS of the ILD and non‐ILD groups were 27% versus 13%(P=
0.078) and 2.7 (95% confidence interval [CI], 1.7–5.3) versus 2.9 months (95% CI 2.1–3.4; …
0.078) and 2.7 (95% confidence interval [CI], 1.7–5.3) versus 2.9 months (95% CI 2.1–3.4; …
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
O Kanai, YH Kim, Y Demura, M Kanai, T Ito… - Thoracic …, 2018 - europepmc.org
Background The risk of developing lung cancer is high in patients with interstitial lung
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are …
[引用][C] Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
O Kanai, YH Kim, Y Demura, M Kanai, T Ito, K Fujita… - Thoracic Cancer, 2018 - cir.nii.ac.jp
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung
disease | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
disease | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …